Biosimilars Imperiled By Big Drug Rebates, FDA Chief Warns
The fledgling industry of lower-cost biosimilars is increasingly imperiled by hefty rebates that are attached to higher-cost biologics in exchange for preferential insurance coverage, the U.S. Food and Drug Administration's leader...To view the full article, register now.
Already a subscriber? Click here to view full article